GH Research (GHRS) Projected to Post Quarterly Earnings on Thursday

GH Research (NASDAQ:GHRS) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

GH Research Stock Up 0.7%

GHRS stock opened at $16.10 on Thursday. The stock’s 50 day moving average is $14.81 and its two-hundred day moving average is $13.99. GH Research has a 52-week low of $7.98 and a 52-week high of $19.51. The company has a market capitalization of $837.65 million, a PE ratio of -21.76 and a beta of 0.99.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new stake in GH Research during the second quarter worth about $79,000. BNP Paribas Financial Markets grew its holdings in shares of GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. UBS Group AG lifted its holdings in shares of GH Research by 11.5% in the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock worth $7,314,000 after purchasing an additional 52,882 shares during the last quarter. Finally, Lynx1 Capital Management LP boosted its position in GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after purchasing an additional 1,854,238 shares during the period. Institutional investors own 56.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Needham & Company LLC set a $29.00 price target on shares of GH Research in a research note on Tuesday, January 6th. TD Cowen reissued a “buy” rating on shares of GH Research in a report on Monday, January 5th. Citigroup restated a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Wolfe Research set a $39.00 price target on shares of GH Research in a research report on Tuesday, January 6th. Finally, HC Wainwright lowered their price objective on GH Research from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GH Research presently has an average rating of “Moderate Buy” and an average target price of $34.11.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.